Cancers with More Genetic Abnormalities May Respond Better to Immunotherapy

Tumors with very many genetic mutations may trigger a strong immune response because they produce enough proteins (antigens) for the immune system to recognize as foreign. Melanoma, bladder and lung cancer are among the most mutated cancers.
Numerous tumor mutations arise from a genetic abnormality called mismatch repair deficiency, suppressing the cell’s ability to repair DNA damage. Scientists think tumors with these abnormalities may be more sensitive to immune checkpoint blockade .
Mismatch Repair Deficiency (MRD) is this DNA repair disorder, occurring in colorectal cancers at approximately 15%. It is less common in stomach, small bowel, endometrial, prostate and ovarian cancers. Lynch syndrome is an example where the abnormality may be inherited. More often, however, MRD develops randomly during life.
Research obtained evidence that tumors with MRD-type DNA repair defects are sensitive to cancer immunotherapy. The FDA subsequently approved Pembrolizumab for treating colorectal cancer patients with MRD.
Researchers also found Pembrolizumab more effective against MRD-associated endometrial, ampullary, duodenal and stomach cancers. Of 7 patients, 5 responded, with average progression-free time of 5.4 months.
Although small, this research opened a possible new treatment option for advanced cancers with MRD. More specifically, it shows that assessing tumor genetics may help identify immunotherapy beneficiaries with less regard to organ of origin. Already, cancers with DNA repair defects are thought potentially more sensitive to PD-1 blockade.
Sources
PD-1 blockade in tumors with mismatch-repair deficiency.
N Engl J Med 372:2509-2520, 2015
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.